MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has initiated the second of two pivotal phase 3 studies of its investigational drug, Qnexa, in overweight and obese patients with comorbidities including hypertension, dyslipidemia, or type 2 diabetes. The CONQUER study (OB-303) will enroll patients with a Body Mass Index (“BMI”) ranging from 27 to 45, including patients with type 2 diabetes regardless of BMI. The co-primary endpoints for these studies will evaluate the differences between treatments from baseline to the end of the treatment period, in mean percent weight loss and in the percentage of subjects achieving weight loss of 5% or more.
